VetUK

Rimifin

Rimifin Tablets for dogs are a plain round flat bevelled edge white tablet with a breakline on the side, available in 50mg and 100mg sized tablets.

Sort by item name Sort by price
Rimifin Tablet 100mg

Rimifin Tablet 100mg

Rimifin tablets contain carprofen Indicated to reduce of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease in dogs. As a follow up to parenteral... [More info]

£0.73
Buy Now
Rimifin Tablet 20mg

Rimifin Tablet 20mg

Rimifin tablets contain carprofen Indicated to reduce of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease in dogs. As a follow up to parenteral... [More info]

£0.26
Buy Now
Rimifin Tablet 50mg

Rimifin Tablet 50mg

Rimifin tablets contain carprofen Indicated to reduce of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease in dogs. As a follow up to parenteral... [More info]

£0.44
Buy Now

Each Rimifin 50mg Tablets for Dogs contains carprofen 50mg, Rimifin 100mg Tablets for Dogs contains carprofen 100mg.

In dogs: Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain following soft tissue surgery.

For oral administration only. 2 to 4mg carprofen per kg bodyweight per day.

An initial dose of 4mg carprofen per kg bodyweight given as a single daily dose or in two equally divided doses may, subject to clinical response be reduced after 7 days to 2mg carprofen/kg bodyweight/day given as a single dose.

Duration of treatment will be dependant upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4mg/kg/day for 2 days as required. Do not exceed the stated dose.

Do not use in cats. Do not use in pregnant or lactating bitches. Do not use in case of hypersensitivity to active substance or to any of the excipients. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Special precautions to be taken by the person administering the product to animals. In the event or accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.

Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrheoa, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.

Carprofen must not be administered with glucocorticoids. Overdose (symptoms, emergency procedures, antidotes) (if necessary)

No signs of toxicity appeared when dogs were treated with Carprofen at levels up to 6 mg/kg twice daily for 7 days (3 times the recommended dose rate of 4mg/kg) and 6mg/kg once daily for a further 7 days. (1.5 times the recommended dose rate of 4 mg/kg).There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

Shelf-life of the veterinary medicinal product as packaged for sale is 3 years. Discard half tablets.Store in a dry place in the original package. Protect from light. Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

Carprofen is a member of the 2-arylpropionic acid group of non-steroidal anti-inflammatory drugs (NSAIDs), and possesses anti-inflammatory, analgesic and antipyretic activity. Carprofen is a chiral drug with the S(+) enantiomer being more active than the R(-) enantiomer. Carprofen, like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However, the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action of carprofen is not clear.

After oral administration, carprofen is well absorbed in the dog. Following the administration of Rimifin tablets in dogs, a mean Cmax (maximum concentration in serum) of 15.8 ng/ml and 12.2 ng/ml was achieved at approximately 2 hours and 1.7 hours for Carprofen R(-) and Carprofen S(+), respectively. For both enantiomers, the mean half-life was approximately 6 hours. The analgesic effect from each dose persists for at least 12 hours.

Carprofen has a small volume of distribution and a low systemic clearance. It is highly bound to plasma protein. Carprofen is metabolised in the liver by conjugation and oxidation. The excretion of the glycuronide conjugate is mainly faecal after biliary excretion.

top